Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade, Inc. (Nasdaq: ACCD) has appointed Kelli Burns as its new senior vice president and chief information security officer as of July 25, 2022. Burns, previously with Ernst & Young and Symetra Financial, brings extensive cybersecurity expertise. She will lead Accolade's information security strategy, enhancing data protection for its over 600 enterprise clients, including major employers and government entities. The move underscores Accolade's commitment to safeguarding customer information as part of its Personalized Healthcare mission.
Priority Health has launched PriorityGPS™, an integrated health navigation and advocacy solution, through a partnership with Accolade (Nasdaq: ACCD). This product targets self-funded large employers, aiming to simplify employee access to benefits. PriorityGPS offers a single point of contact for support, including appointment scheduling and coverage guidance. The collaboration enhances personalized healthcare and is designed to improve employee engagement while lowering costs. Priority Health continues to prioritize quality care for its members.
Accolade, Inc. (NASDAQ: ACCD) reported a strong fiscal first quarter 2023, achieving revenue of $85.5 million, a 44% increase from $59.5 million in the same quarter last year. Despite a significant net loss of $342.8 million due to a goodwill impairment charge, adjusted gross profit rose 63% to $39.0 million, with an adjusted gross margin of 45.6%. The company raised its revenue guidance midpoint, reflecting confidence in its business model and market demand for personalized healthcare solutions amidst ongoing challenges in the healthcare system.
Accolade (Nasdaq: ACCD) will showcase its Personalized Healthcare solutions at AHIP 2022 from June 21-23 in Las Vegas. The company aims to meet the needs of health plans seeking virtual-first care options. Key presentations include Dr. Shantanu Nundy discussing a post-pandemic framework for chronic care and Dr. Anupam Goel addressing virtual care for chronic diseases. Accolade emphasizes its partnership with Priority Health to enhance member engagement and satisfaction in Michigan by integrating virtual and in-person healthcare services.
Accolade, Inc. (NASDAQ: ACCD) will release its fiscal Q1 2023 financial results on June 30, 2022, after market close. A conference call is scheduled for 4:30 p.m. E.T. the same day to discuss the results. This healthcare provider serves over 600 employers, delivering personal and value-based healthcare solutions to millions of members. Accolade's services include virtual primary care and mental health support, consistently achieving consumer satisfaction ratings over 90%. For more details, visit ir.accolade.com.
Accolade, Inc. (NASDAQ: ACCD) has announced its participation in several upcoming investor conferences. The events include:
- June 8: Stifel 2022 Cross Sector Insight Conference at 4:10 pm ET in Boston
- June 9: 42nd Annual William Blair Growth Stock Conference at 3:00 pm ET in Chicago
- June 16: Goldman Sachs 43rd Annual Global Healthcare Conference at 12:20 pm ET in Rancho Palos Verdes, CA
Details and webcasts from these conferences will be available at ir.accolade.com.
Accolade, Inc. (NASDAQ: ACCD) announced its participation in two upcoming investor conferences. The first is on May 12 at 1pm ET at the BofA Securities 2022 Healthcare Conference in Las Vegas, and the second is on May 16 at 9:30am ET at the virtual 17th Annual Needham Technology & Media Conference. Accolade aims to enhance healthcare experiences through personalized, data-driven solutions, boasting consumer satisfaction ratings exceeding 90%. Webcasts will be available at ir.accolade.com for those interested.
Accolade (Nasdaq: ACCD) has launched Medication Integrated Care, a new solution aimed at helping employers tackle rising prescription drug costs and complications in medication management. With employer health plan costs climbing sharply, particularly a 7.4% increase in prescription drug spending in 2021, this service combines pharmacist-led medication therapy management with advanced analytics from Rx Savings Solutions. By identifying high-risk members, Medication Integrated Care aims to reduce both out-of-pocket expenses and hospital admissions, ultimately improving the overall healthcare experience for employees.
Accolade (Nasdaq: ACCD) appointed Jennifer Hanson as Chief Human Resources Officer and Executive Vice President of People and Culture as of May 2, 2022. She will oversee employee experience across eight global offices, enhancing engagement and professional growth. With over 20 years in healthcare HR, Hanson aims to attract and retain top talent in a growing employer healthcare market. CEO Rajeev Singh highlighted her innovation experience as vital for fostering a strong workplace culture amidst a transformative period for healthcare.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
